Literature DB >> 12814397

Alternative sources of beta cells for cell therapy of diabetes.

R Scharfmann1.   

Abstract

Type 1 and type 2 diabetes affect 150 million people worldwide. This is a result of the incapacity of pancreatic beta cells to produce and secrete enough insulin. Transplantation of pancreatic beta cells represents a potential therapeutic approach for type 1 diabetes. However, one limitation is the insufficient amount of beta cells available for grafts. Alternative sources of beta cells have yet to be defined. During the past years, progress has been made in the definition of new strategies to produce mature pancreatic beta cells. Different cell sources are currently tested for their capacity to differentiate into mature beta cells. In this review, I will summarize the status of our knowledge in the field of cell therapy for diabetes.

Entities:  

Mesh:

Year:  2003        PMID: 12814397     DOI: 10.1046/j.1365-2362.2003.01190.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  Differentiation of dermis-derived multipotent cells into insulin-producing pancreatic cells in vitro.

Authors:  Chun-Meng Shi; Tian-Min Cheng
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

2.  Endocrine precursor cells from mouse islets are not generated by epithelial-to-mesenchymal transition of mature beta cells.

Authors:  Russell A Morton; Elizabeth Geras-Raaka; Leah M Wilson; Bruce M Raaka; Marvin C Gershengorn
Journal:  Mol Cell Endocrinol       Date:  2007-02-15       Impact factor: 4.102

3.  Proliferation and pluripotency of human embryonic stem cells maintained on type I collagen.

Authors:  Meredith B Jones; Chia H Chu; James C Pendleton; Michael J Betenbaugh; Joseph Shiloach; Bolormaa Baljinnyam; Jeffrey S Rubin; Michael J Shamblott
Journal:  Stem Cells Dev       Date:  2010-10-12       Impact factor: 3.272

Review 4.  Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.

Authors:  Pads Palihaderu; Bilm Mendis; Jmkjk Premarathne; Wkrr Dias; Swee Keong Yeap; Wan Yong Ho; A S Dissanayake; I H Rajapakse; P Karunanayake; U Senarath; D A Satharasinghe
Journal:  Epigenet Insights       Date:  2022-10-15

5.  MicroRNA-34c acts as a bidirectional switch in the maturation of insulin-producing cells derived from mesenchymal stem cells.

Authors:  Chunyu Bai; Yuhua Gao; Xiangyang Zhang; Wancai Yang; Weijun Guan
Journal:  Oncotarget       Date:  2017-10-16

6.  Isolation of pancreatic progenitor cells with the surface marker of hematopoietic stem cells.

Authors:  Fengxia Ma; Fang Chen; Ying Chi; Shaoguang Yang; Shihong Lu; Zhongchao Han
Journal:  Int J Endocrinol       Date:  2012-12-20       Impact factor: 3.257

Review 7.  Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy.

Authors:  Meng Liu; Zhong Chao Han
Journal:  J Cell Mol Med       Date:  2008-02-24       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.